
In a zzso zzso trial, 205 zzso episodes in zzso cancer patients were treated with zzso with or without zzso zzso zzso zzso both agents being administered only if the initial zzso count was below zzso or zzso plus zzso zzso + zzso The overall response rate was zzso zzso of 60 for C zzso T and 45 of 58 for C + zzso zzso zzso analyses documented no evidence of a significant difference between the two regimens in overall treatment effect after accounting for the linear effects of potentially important zzso such as infection type and zzso zzso Although the response rates for the zzso of patients with zzso was better with the C + P regimen zzso zzso zzso there was no difference in response for patients with zzso and profound zzso zzso sustained zzso The double zzso combination demonstrated in zzso zzso in zzso antagonism was not zzso Both regimens produced excellent serum zzso levels zzso zzso T geometric mean peak zzso C + P peak zzso against zzso but not zzso pathogens zzso zzso zzso that had caused zzso zzso of resistance and significant zzso and/or bleeding did not occur during zzso zzso zzso was noted in 7 of 95 trials in the C + P and in 6 of 89 trials in the C zzso T group zzso zzso zzso The zzso of secondary infections in patients with profound zzso zzso sustained zzso was lower in the C zzso T group zzso zzso zzso zzso canal zzso zzso preservation with C zzso zzso and suppression with C + zzso was zzso zzso AT 250 zzso 

